Building Frameworks to Expand MRD Testing and Guide Treatment Selection for Newly Diagnosed Patients with Multiple Myeloma

March 7, 2025
Carolina Blood and Cancer Care Associates
 
Multiple myeloma is the second most prevalent blood cancer globally and in 2024, over 35,000 individuals in the United States will receive a diagnosis, with more than 12,000 fatalities expected from the condition. Achieving a strong response to initial therapy is critical for newly diagnosed multiple myeloma (NDMM) patients, as the first remission typically lasts the longest, and patient attrition with subsequent therapies due to comorbidities, disease progression, and cumulative adverse effects from treatments is common. Given the advanced age and comorbidities common among patients with MM at diagnosis, it is crucial to administer the best available treatments upfront rather than saving them for relapse. Fortunately, the inclusion of anti-CD38 monoclonal antibodies in quadruplet regimens has led to deep and durable responses in patients with NDMM, marking a paradigm shift in this treatment setting. However, the rapid pace of these developments along with ongoing questions and uncertainties regarding the role of minimal residual disease (MRD) has added complexity in this space. Using expert-developed, peer-reviewed content, leaders at cancer centers will facilitate a 1-hour learning and action planning program with their clinical team to navigate this complexity and align their therapeutic paradigms with the latest evidence.
 
Educational Partner: Academy for Continued Healthcare Learning (ACHL)

Commercial Support: This program is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

This program is intended for oncologists, hematologists, pathologists, and the multidisciplinary team who manage patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Appraise the role of measurable residual disease (MRD) as a prognostic marker in newly diagnosed multiple myeloma (NDMM) and its implications for patient outcomes
  • Evaluate the efficacy and safety profiles of novel quadruplet regimens, including anti-CD38 monoclonal antibodies, in the treatment of both transplant-eligible and -ineligible NDMM patients
  • Design comprehensive treatment plans for NDMM patients that incorporate best practices, including novel therapeutic combinations and MRD monitoring, to achieve deep and durable responses
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
ACHL
CME Coordinator Contact Phone: 
877-444-8435 ext 160

You may also be interested in

22nd Annual International Ultmann Chicago Lymphoma Symposium
Westin Chicago River North | Chicago, IL
 
The goal of this educational activity is to facilitate a forum for physicians, researchers, and other allied healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin Lymphoma.
28th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium
David Rubenstein Forum | Chicago, IL
 
The goals of this activity are for participants to examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rationale for and the results of studies that include novel agents to treat patients with advanced cancer.
2nd Annual University of Chicago Practice Updates in Hematology and Oncology
Hilton Chicago/Oak Brook Hills Resort & Conference Center | Oak Brook, IL
 
This activity will enhance cancer care and improve patient outcomes across the Midwest. It will equip healthcare professionals with the latest evidence-based strategies for diagnosing and managing a broad range of solid organ and hematologic malignancies.
Summary
Event starts: 
03/07/2025 - 12:00pm
Event ends: 
03/07/2025 - 1:00pm
Activity opens: 
03/07/2025
Activity expires: 
06/07/2025
Add to calendar: 
Webinar
Rock Hill, SC
United States
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website!
 
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org/.

The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO FACULTY
  Benjamin Derman, MD
  Assistant Professor
  Medicine, Section of Hematology/Oncology
  University of Chicago
  Chicago, IL
 
 
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
 
Completion of this activity, including the posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information via email after receiving your certificate.
REGISTRATION: Registration is not open to the public.
For questions or more information, visit the ACHL website or click the button below!
 
Please login or create an account to proceed.